Literature DB >> 23183114

High nuclear expression of phosphorylated extracellular signal-regulated kinase in tumor cells in colorectal glands is associated with poor outcome in colorectal cancer.

Cheng-Jeng Tai1, Ching-Hsiao Lee, Hung-Chang Chen, Hsin-Kai Wang, Ming-Chung Jiang, Tzu-Cheng Su, Ko-Hung Shen, Shu-Hui Lin, Chung-Min Yeh, Chih-Jung Chen, Kun-Tu Yeh, Chun-Chao Chang.   

Abstract

Extracellular signal-regulated kinase (ERK) is a major downstream transducer of Ras and plays an important role in transducing extracellular signals to the nuclei of cells. It is located in both the cytoplasm and the nucleus of cells. The nuclear localization of phosphorylated or activated ERK is involved in the invasive behavior of tumor cells. We studied the association between Ras mutation/ERK activation and the prognosis of patients with colorectal cancer. We analyzed 126 surgically resected colorectal cancer specimens for K-Ras mutation using direct sequencing. Activation/phosphorylation of ERK was assayed by immunohistochemistry with tissue microarray, and the staining intensity was analyzed using a semiquantitative scoring system. K-Ras mutations were detected in 32.5% (41/126) of the colorectal tumors. Colorectal glands are important functional organs in colorectal tissue and form the origin of colorectal carcinomas. Tissue microarray immunohistochemistry tests showed that tumors in colorectal cancer specimens were significantly stained for phospho-ERK (100%; 126/126), whereas nonneoplastic colorectal glands mainly showed faint phosphorylated ERK staining. High nuclear phospho-ERK expression in tumors was associated with highly invasive cancer stage and T status of the disease. Kaplan-Meier analysis showed that nuclear but not cytoplasmic phosphorylated ERK expression correlated with the patients' overall survival rate (P = .039). Colorectal adenomas including tubular adenomas and tubulovillous adenomas mainly showed weak cytoplasmic phospho-ERK expression. Our results suggest that immunohistologic analysis of phosphorylated ERK expression in colorectal glands may aid the diagnosis of colorectal cancer and that nuclear phosphorylated ERK might be a valuable prognostic marker for colorectal cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183114     DOI: 10.1016/j.anndiagpath.2012.09.004

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  5 in total

1.  Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.

Authors:  Ting Deng; Hong Pan; Rubing Han; Dingzhi Huang; Hongli Li; Likun Zhou; Xia Wang; Ming Bai; Xiang Li; Rui Liu; Shaohua Ge; Tao Ning; Le Zhang; Yi Ba
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Authors:  Stergios J Moschos; Ryan J Sullivan; Wen-Jen Hwu; Ramesh K Ramanathan; Alex A Adjei; Peter C Fong; Ronnie Shapira-Frommer; Hussein A Tawbi; Joseph Rubino; Thomas S Rush; Da Zhang; Nathan R Miselis; Ahmed A Samatar; Patrick Chun; Eric H Rubin; James Schiller; Brian J Long; Priya Dayananth; Donna Carr; Paul Kirschmeier; W Robert Bishop; Yongqi Deng; Alan Cooper; Gerald W Shipps; Blanca Homet Moreno; Lidia Robert; Antoni Ribas; Keith T Flaherty
Journal:  JCI Insight       Date:  2018-02-22

Review 3.  The potential role of leptin in tumor invasion and metastasis.

Authors:  Amitabha Ray; Margot P Cleary
Journal:  Cytokine Growth Factor Rev       Date:  2017-11-11       Impact factor: 7.638

4.  Puerarin Suppress Apoptosis of Human Osteoblasts via ERK Signaling Pathway.

Authors:  Ling-Juan Liu; Li-Qun Liu; Tao Bo; Shi-Jun Li; Zhen Zhu; Rong-Rong Cui; Ding-An Mao
Journal:  Int J Endocrinol       Date:  2013-06-12       Impact factor: 3.257

5.  CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.

Authors:  Xiao-Fang Wei; You-Fan Feng; Qiao-Lin Chen; Qi-Ke Zhang
Journal:  Cancer Cell Int       Date:  2018-07-09       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.